Improving the targeting of therapeutics with single-domain antibodies

Kendrick B. Turner, Nathan Alves, Igor L. Medintz, Scott A. Walper

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Introduction: The targeted delivery of therapeutic agents greatly increases their effectiveness while simultaneously reducing negative side effects. In the past, targeting of therapeutics has been accomplished with nucleic acids, peptides/proteins, and conventional antibodies. A promising alternative to the conventional antibodies often used in therapeutic targeting are significantly smaller-sized antibody fragments known as single-domain antibodies (sdAbs).Areas Covered: Recent advances in the utility of sdAbs for targeting of therapeutic agents along with relevant examples from the literature are discussed. Their advantages when compared to other targeting strategies as well as their challenges and limitations is also covered.Expert Opinion: The development of sdAb-based targeted therapeutics will likely continue. The identification of novel protein modification techniques will provide more options for sdAb modification (conjugation, immobilization, functionalization), allowing a wider array of therapeutic agents to be successfully targeted and delivered using sdAbs. This will also spur the selection of sdAbs with specificity for other targets having relevance towards therapeutics.

Original languageEnglish (US)
Pages (from-to)561-570
Number of pages10
JournalExpert Opinion on Drug Delivery
Volume13
Issue number4
DOIs
StatePublished - Apr 2 2016
Externally publishedYes

Fingerprint

Single-Domain Antibodies
Therapeutics
Peptide Nucleic Acids
Immunoglobulin Fragments
Antibody Specificity
Antibodies
Expert Testimony
Immobilization
Proteins

Keywords

  • antibody drug conjugate (ADC)
  • bioconjugation
  • nanoparticle
  • single-domain antibodies (sdAb)
  • targeted delivery

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Improving the targeting of therapeutics with single-domain antibodies. / Turner, Kendrick B.; Alves, Nathan; Medintz, Igor L.; Walper, Scott A.

In: Expert Opinion on Drug Delivery, Vol. 13, No. 4, 02.04.2016, p. 561-570.

Research output: Contribution to journalReview article

Turner, Kendrick B. ; Alves, Nathan ; Medintz, Igor L. ; Walper, Scott A. / Improving the targeting of therapeutics with single-domain antibodies. In: Expert Opinion on Drug Delivery. 2016 ; Vol. 13, No. 4. pp. 561-570.
@article{1a11a60fb5404f29b91643a8f846768b,
title = "Improving the targeting of therapeutics with single-domain antibodies",
abstract = "Introduction: The targeted delivery of therapeutic agents greatly increases their effectiveness while simultaneously reducing negative side effects. In the past, targeting of therapeutics has been accomplished with nucleic acids, peptides/proteins, and conventional antibodies. A promising alternative to the conventional antibodies often used in therapeutic targeting are significantly smaller-sized antibody fragments known as single-domain antibodies (sdAbs).Areas Covered: Recent advances in the utility of sdAbs for targeting of therapeutic agents along with relevant examples from the literature are discussed. Their advantages when compared to other targeting strategies as well as their challenges and limitations is also covered.Expert Opinion: The development of sdAb-based targeted therapeutics will likely continue. The identification of novel protein modification techniques will provide more options for sdAb modification (conjugation, immobilization, functionalization), allowing a wider array of therapeutic agents to be successfully targeted and delivered using sdAbs. This will also spur the selection of sdAbs with specificity for other targets having relevance towards therapeutics.",
keywords = "antibody drug conjugate (ADC), bioconjugation, nanoparticle, single-domain antibodies (sdAb), targeted delivery",
author = "Turner, {Kendrick B.} and Nathan Alves and Medintz, {Igor L.} and Walper, {Scott A.}",
year = "2016",
month = "4",
day = "2",
doi = "10.1517/17425247.2016.1133583",
language = "English (US)",
volume = "13",
pages = "561--570",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Improving the targeting of therapeutics with single-domain antibodies

AU - Turner, Kendrick B.

AU - Alves, Nathan

AU - Medintz, Igor L.

AU - Walper, Scott A.

PY - 2016/4/2

Y1 - 2016/4/2

N2 - Introduction: The targeted delivery of therapeutic agents greatly increases their effectiveness while simultaneously reducing negative side effects. In the past, targeting of therapeutics has been accomplished with nucleic acids, peptides/proteins, and conventional antibodies. A promising alternative to the conventional antibodies often used in therapeutic targeting are significantly smaller-sized antibody fragments known as single-domain antibodies (sdAbs).Areas Covered: Recent advances in the utility of sdAbs for targeting of therapeutic agents along with relevant examples from the literature are discussed. Their advantages when compared to other targeting strategies as well as their challenges and limitations is also covered.Expert Opinion: The development of sdAb-based targeted therapeutics will likely continue. The identification of novel protein modification techniques will provide more options for sdAb modification (conjugation, immobilization, functionalization), allowing a wider array of therapeutic agents to be successfully targeted and delivered using sdAbs. This will also spur the selection of sdAbs with specificity for other targets having relevance towards therapeutics.

AB - Introduction: The targeted delivery of therapeutic agents greatly increases their effectiveness while simultaneously reducing negative side effects. In the past, targeting of therapeutics has been accomplished with nucleic acids, peptides/proteins, and conventional antibodies. A promising alternative to the conventional antibodies often used in therapeutic targeting are significantly smaller-sized antibody fragments known as single-domain antibodies (sdAbs).Areas Covered: Recent advances in the utility of sdAbs for targeting of therapeutic agents along with relevant examples from the literature are discussed. Their advantages when compared to other targeting strategies as well as their challenges and limitations is also covered.Expert Opinion: The development of sdAb-based targeted therapeutics will likely continue. The identification of novel protein modification techniques will provide more options for sdAb modification (conjugation, immobilization, functionalization), allowing a wider array of therapeutic agents to be successfully targeted and delivered using sdAbs. This will also spur the selection of sdAbs with specificity for other targets having relevance towards therapeutics.

KW - antibody drug conjugate (ADC)

KW - bioconjugation

KW - nanoparticle

KW - single-domain antibodies (sdAb)

KW - targeted delivery

UR - http://www.scopus.com/inward/record.url?scp=84961210069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961210069&partnerID=8YFLogxK

U2 - 10.1517/17425247.2016.1133583

DO - 10.1517/17425247.2016.1133583

M3 - Review article

C2 - 26689649

AN - SCOPUS:84961210069

VL - 13

SP - 561

EP - 570

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 4

ER -